Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

Podcast: Emerging Checkpoint Inhibitor"Based Strategies for Advanced Endometrial Cancer

Access Activity

Overview / Abstract:

This expert-led episode of Oncology Data Advisor TM, presented by leading experts Ritu Salani, MD, Director of the Division of Gynecologic Oncology and Professor of Obstetrics and Gynecology at the University of California, Los Angeles (UCLA), and Floor Backes, MD, Professor of Obstetrics and Gynecology at The Ohio State University College of Medicine.ain expert insight and enhance your clinical knowledge with this case-based activity focusing on the pathology, treatment, and management of advanced endometrial cancer, Start the activity now!

STATEMENT OF NEED

Cancer of the uterine corpus, also called endometrial cancer (EC), is the most common cancer of the female genital tract, with an estimated 65,950 new cases diagnosed and 12,550 deaths annually in the United States (ACS, 2022). The mortality rate has increased approximately 1% each year from 2015 to 2019, an increase which may be related to a higher rate of advanced-stage cancers, high-risk histologies, and patients being diagnosed at an older age (ACS, 2022). There are significant disparities between White and Black women regarding rates of early-stage diagnosis (75% vs 62%) and 5-year relative survival (84% vs 63%) (ACS, 2022). When patients are diagnosed with distant-stage disease, 5-year relative survival rates plummet to 18% for all races. Early identification of high-risk patients and personalized treatment approaches for this complex, multifaceted disease are needed to improve outcomes. In this activity, Ritu Salani, MD, Director of the Division of Gynecologic Oncology and Professor of Obstetrics and Gynecology at the University of California, Los Angeles (UCLA), and Floor Backes, MD, Professor of Obstetrics and Gynecology at The Ohio State University College of Medicine, will update learners on the latest research in the pathology, molecular characterization, treatment, and management of endometrial cancer.

TARGET AUDIENCE

Gynecologic oncologists, medical oncologists, surgical oncologists, nurse practitioners, physician associates, oncology nurses, and other health care professionals involved in the treatment of patients with endometrial cancer.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to
Assess molecular characteristics of advanced endometrial cancer that can inform prognosis and therapeutic selection
Evaluate the scientific rationale for targeting the immune microenvironment in the treatment of endometrial cancer
Appraise the efficacy and safety of emerging checkpoint inhibitor-based therapies for advanced endometrial cancer

Expiration

May 09, 2023

Discipline(s)

Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME

Format

Podcast

Credits / Hours

0.75 CME | 0.75 NCPD | MOC | ILNA

Accreditation

ACCME, ONCC, ANCC

Presenters / Authors / Faculty

Ritu Salani, MD, MBA (Chairperson)
Director, Division of Gynecologic Oncology
Professor, Department of Obstetrics and Oncology
David Geffen School of Medicine
University of California, Los Angeles

Floor J. Backes, MD
Gynecologic Oncologist
Professor, Obstetrics and Oncology
The Ohio State University College of Medicine
James Cancer Hospital

Sponsors / Supporters / Grant Providers

This activity is supported by an independent educational grant from Merck.

Keywords / Search Terms

Oncology, i3 Health, CME, NCPD, free CNE, free NCPD, Free CE, Free CME, Nursing, Oncology Nursing, Physician, Endometrial Cancer, Endometrium, Uterus, Oncologist

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map